STROX BIOPHARMACEUTICALS

STROX Biopharmaceuticals, LLC ("STROX" or the "Company") is an early-stage company engaged in the development of anti-bacterial antibody products for treatment of life-threatening infections. The Company's lead product is an antibody for treating hospital-acquired Staphylococcus aureus (SA) infections, including those caused by methicillin-resistant SA (MRSA). Unlike conventional antibiotics, this innovative antibody product specifically directs components of the body's immune system to bind and then kill SA bacteria... Hospital-acquired SA infections are a leading cause of disability and death, and have placed a tremendous economic burden on healthcare systems throughout the world. Analysis of 2000-2001 U.S. hospital data showed that inpatients with SA infection as a discharge diagnosis had, on average, three times the length of hospital stay, three times the total charges, and five times the risk of in-hospital death than patients without infection. This translates to roughly an..

Also known as: STROX Biopharmaceuticals, LLC

Primary location: Wellington United States